Journal of Biological Chemistry · 2001 · 74 citations · 32 references
MedicineMolecular BiologyPharmacologyCell SignalingPharmacodynamicsSignal TransductionLigand BindingReceptor PharmacologyReceptor PhysiologyReceptor RegulationReceptor-ligand InteractionsReceptor-mediated SignalingConstitutive Receptor Activity
The B1 bradykinin (BK) receptor (B1R) is a seven-transmembrane domain, G protein-coupled receptor that is induced by injury and important in inflammation and nociception. Here, we show that the human B1R exhibits a high level of ligand-independent, constitutive activity. Constitutive activity was identified by the increase in basal cellular phosphoinositide hydrolysis as a function of the density of the receptors in transiently transfected HEK293 cells. Several B1R peptide antagonists were neutral antagonists or very weakly efficacious inverse agonists. Constitutive B1R activity was further increased by alanine mutation of Asn121 in the third transmembrane domain of the receptor (B1A121). This mutant resembled the agonist-preferred receptor state since it also exhibited increased agonist affinity and decreased agonist responsiveness. A dramatic loss of constitutive activity occurred when the fourth intracellular C-terminal domain (IC-IV) of the human B2 BK receptor subtype (B2R), which exhibits minimal constitutive activity, was substituted in either B1R or B1A121 to make B1(B2ICIV) and B1(B2ICIV)A121, respectively. Activity was partially recovered by subsequent alanine mutation of a cluster of two serines and two threonines in IC-IV of either B1(B2ICIV) or B1(B2ICIV)A121, a cluster that is important for B2R desensitization. The ligand-independent, constitutive activity of B1R therefore depends on epitopes in both transmembrane and intracellular domains. We propose that the activity is primarily due to the lack of critical epitopes in IC-IV that regulate such activity. The B1 bradykinin (BK) receptor (B1R) is a seven-transmembrane domain, G protein-coupled receptor that is induced by injury and important in inflammation and nociception. Here, we show that the human B1R exhibits a high level of ligand-independent, constitutive activity. Constitutive activity was identified by the increase in basal cellular phosphoinositide hydrolysis as a function of the density of the receptors in transiently transfected HEK293 cells. Several B1R peptide antagonists were neutral antagonists or very weakly efficacious inverse agonists. Constitutive B1R activity was further increased by alanine mutation of Asn121 in the third transmembrane domain of the receptor (B1A121). This mutant resembled the agonist-preferred receptor state since it also exhibited increased agonist affinity and decreased agonist responsiveness. A dramatic loss of constitutive activity occurred when the fourth intracellular C-terminal domain (IC-IV) of the human B2 BK receptor subtype (B2R), which exhibits minimal constitutive activity, was substituted in either B1R or B1A121 to make B1(B2ICIV) and B1(B2ICIV)A121, respectively. Activity was partially recovered by subsequent alanine mutation of a cluster of two serines and two threonines in IC-IV of either B1(B2ICIV) or B1(B2ICIV)A121, a cluster that is important for B2R desensitization. The ligand-independent, constitutive activity of B1R therefore depends on epitopes in both transmembrane and intracellular domains. We propose that the activity is primarily due to the lack of critical epitopes in IC-IV that regulate such activity. bradykinin G protein-coupled receptor kallidin phosphoinositide wild-type fourth intracellular domain third transmembrane domain Dulbecco's modified Eagle's medium index of agonist-promoted receptor activity index of basal receptor activity The B1 and B2 bradykinin (BK)1 receptors are seven-transmembrane domain, G protein-coupled receptors (GPCR) (1Hess J.F. Borkowski J.A. Young G.S. Strader C.D. Ransom R.W. Biochem. Biophys. Res. Commun. 1992; 184: 260-268Crossref PubMed Scopus (447) Google Scholar, 2Menke J.G. Borkowski J.A. Bierilo K.K. MacNeil T. Derrick A.W. Schneck K.A. Ransom R.W. Strader C.D. Linemeyer D.L. Hess J.F. J. Biol. Chem. 1994; 269: 21583-21586Abstract Full Text PDF PubMed Google Scholar), which mediate the actions of kinins (3Regoli D. Barabe J. Pharmacol. Rev. 1980; 32: 1-46Crossref PubMed Scopus (16) Google Scholar), pro-inflammatory peptides formed in response to tissue injury from kininogen precursors (4Proud D. Kaplan A.P. Annu. Rev. Immunol. 1988; 6: 49-83Crossref PubMed Scopus (380) Google Scholar, 5Bhoola K.D. Figueroa C.D. Worthy K. Pharmacol. Rev. 1992; 44: 1-80PubMed Google Scholar). Kinin actions include pain, inflammation, and hyperalgesia (4Proud D. Kaplan A.P. Annu. Rev. Immunol. 1988; 6: 49-83Crossref PubMed Scopus (380) Google Scholar, 6Dray A. Perkins M. Trends Neurosci. 1993; 16: 99-104Abstract Full Text PDF PubMed Scopus (563) Google Scholar). The B2 receptor mediates the actions of BK and Lys-BK or kallidin (KD), the first set of bioactive kinins formed following injury, whereas the B1 receptor is thought to mediate the actions of des-Arg9-BK and des-Arg10-KD, the carboxypeptidase products of BK and KD and the second set of bioactive kinins formed (3Regoli D. Barabe J. Pharmacol. Rev. 1980; 32: 1-46Crossref PubMed Scopus (16) Google Scholar). Despite binding very similar ligands, leading to their classification as receptor subtypes, these receptors exhibit only 36% identity. Furthermore, the B2 receptor is constitutively expressed, whereas the B1 receptor is expressed at very low levels, if at all, in healthy tissue but is induced by inflammatory stimuli such as interleukin-1μ (2Menke J.G. Borkowski J.A. Bierilo K.K. MacNeil T. Derrick A.W. Schneck K.A. Ransom R.W. Strader C.D. Linemeyer D.L. Hess J.F. J. Biol. Chem. 1994; 269: 21583-21586Abstract Full Text PDF PubMed Google Scholar, 7Marceau F. Hess J.F. Bachvarov D.R. Pharmacol. Rev. 1998; 50: 357-386PubMed Google Scholar, 8Phagoo S.B. Poole S. Leeb-Lundberg L.M.F. Mol. Pharmacol. 1999; 56: 325-333Crossref PubMed Scopus (118) Google Scholar, 9Davis A.J. Perkins M.N. Br. J. Pharmacol. 1994; 113: 63-68Crossref PubMed Scopus (135) Google Scholar) and by kinins themselves (8Phagoo S.B. Poole S. Leeb-Lundberg L.M.F. Mol. Pharmacol. 1999; 56: 325-333Crossref PubMed Scopus (118) Google Scholar, 10Schanstra J.P. Bataille E. Marin Castano M.E. Barascud Y. Hirtz C. Pesquero J.B. Pecher C. Gauthier F. Girolami J.P. Bascands J.L. J. Clin. Invest. 1998; 101: 2080-2091Crossref PubMed Scopus (169) Google Scholar). This pattern of expression is consistent with the fact that the B2 receptor appears to be the principal kinin receptor under healthy conditions and in the acute stage of the inflammatory response (4Proud D. Kaplan A.P. Annu. Rev. Immunol. 1988; 6: 49-83Crossref PubMed Scopus (380) Google Scholar, 6Dray A. Perkins M. Trends Neurosci. 1993; 16: 99-104Abstract Full Text PDF PubMed Scopus (563) Google Scholar, 11Steranka L.R. Manning D.C. DeHaas C.J. Ferkany J.W. Borosky S.A. Connor J.R. Vavrek R.J. Stewart J.M. Snyder S.H. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 3245-3249Crossref PubMed Scopus (369) Google Scholar, 12Dray A. Can. J. Physiol. Pharmacol. 1997; 75: 704-712Crossref PubMed Scopus (112) Google Scholar), whereas the B1 receptor is important primarily in the chronic stage of the response (6Dray A. Perkins M. Trends Neurosci. 1993; 16: 99-104Abstract Full Text PDF PubMed Scopus (563) Google Scholar, 13Farmer S.G. McMillan B.A. Meeker S.N. Burch R.M. Agents Actions. 1991; 34: 191-193Crossref PubMed Scopus (50) Google Scholar,14Pesquero J.B. Araujo R.C. Heppenstall P.A. Stucky C.L. Silva Jr., J.A. Walther T. Oliveira S.M. Pesquero J.L. Paiva A.C.M. Calixto J.B. Lewin G. Bader M. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 8140-8145Crossref PubMed Scopus (327) Google Scholar). The rationale for restricting B1 receptor expression primarily to conditions of injury is not understood. One explanation is that this receptor serves to provide a sustained kinin signal (7Marceau F. Hess J.F. Bachvarov D.R. Pharmacol. Rev. 1998; 50: 357-386PubMed Google Scholar), which may be necessary in inflammation but detrimental under healthy conditions. This explanation is consistent with the fact that the B2 receptor response is transient and rapidly desensitizes upon agonist stimulation, whereas the B1 receptor response is sustained and desensitizes very slowly (15Bascands J.L. Pecher C. Rouaud S. Emond C. Tack J.L. Bastie M.J. Burch R. Regoli D. Girolami J.P. Am. J. Physiol. 1993; 264: F548-F556PubMed Google Scholar, 16Mathis S.A. Criscimagna N.L. Leeb-Lundberg L.M.F. Mol. Pharmacol. 1996; 50: 128-129PubMed Google Scholar). However, restricting B1 receptor expression to prohibit sustained agonist stimulation seems unnecessary since kinin in the of injury is and the in of the B1 receptor des-Arg9-BK and by from BK and is Burch R.M. Scholar). the B1 receptor expression be important if this receptor is constitutively since constitutive activity, which both and in response to in these to Biol. 1994; 6: PubMed Scopus Google Scholar, A.J. M. S.M. Jr., Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar) J. J. C. J. J. G. 1993; PubMed Scopus Google Scholar, E. A. E. 1997; PubMed Scopus Google Scholar). The of and constitutively in transmembrane to the that are important in the of these receptors the and the constitutive activity A. S. J. Res. 1997; PubMed Scopus Google Scholar). at a two by in the B2 BK J. C. D. T. R. C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar) and receptors T. R. C. J. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar) and by a in the receptor J. R. M. F. R.M. Mol. Pharmacol. 1996; Google Scholar) and in 1992; PubMed Scopus Google Scholar), are thought to in such a that epitopes in IC-IV also regulate constitutive activity D.R. Y. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, M. A. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar, S. J. J. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar, S. M. C. J. A. J. Biol. Chem. 1999; Scholar, T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar), is the We that the B2 receptor exhibits minimal activity. of a cluster of serines and threonines in which is important for agonist-promoted B2 receptor and A. A. F. R.M. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar) and T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar), this activity T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). the we show that the human B1 receptor exhibits a high level of constitutive activity in HEK293 cells. B2R IC-IV B1R activity, and this of the state of the The is partially due to the of critical serines and but epitopes are also we propose that the high constitutive B1R activity is due to the lack of epitopes in and were from the were from and and were from whereas and were from and were from D. J. was a from D. was a from F. The human and B1 receptor and human B2 receptor were from F. were as S.A. T. Leeb-Lundberg L.M.F. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar, Leeb-Lundberg L.M.F. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). were a as S.A. T. Leeb-Lundberg L.M.F. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). The was at the receptor following the HEK293 human were in with in at The were transiently transfected with of the as A. A. F. R.M. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). HEK293 were with and by at for The were in a and and tissue at for were by at for at and in the on the The were in the with and and The was in the the of agonist and binding to the B1 and B2 receptors and A and binding the was the of from to in increase in the of the binding and for on the B1 receptor of antagonists on and hydrolysis of the human B1 of HEK293 transfected with B1 receptors were in the and of of peptide antagonists as and for binding a of The are of with in from these are in HEK293 were transfected with B1 receptors and with and and in the and of as and under The were for The are as of is the hydrolysis in and was The density of the receptors was cells. The are of at with in with des-Arg9-BK of B1 receptor peptide antagonists and their binding on B1 of transiently transfected were to were by the in binding a of the agonist and of the peptide The are as the of at of transiently transfected were to were by the in binding a of the agonist and of the peptide The are as the of at in a binding were as T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar, S.A. T. Leeb-Lundberg L.M.F. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). density was on HEK293 by in the and and a of or at for binding was on by the in binding or with and of at for of receptor were by hydrolysis in HEK293 T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). hydrolysis was in with in the were in medium in the and of agonist or for at and antagonists were the was the of the agonist and further for HEK293 transfected with receptors were to and as Leeb-Lundberg L.M.F. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). were in for at The was at at The was with by with to for at The were with of and with of The was in for at and on The was and with were with to the by the are as the and were the The receptor binding for were by the from binding The human B1 receptor transiently expressed in HEK293 exhibited a agonist as by both receptor binding and A and that des-Arg10-KD, a B1 to the B1 receptor with affinity and hydrolysis with a which were and of of BK a B2 This was from that of the human B2 receptor subtype transiently expressed in HEK293 to which BK with affinity and hydrolysis with a which were of of constitutive B1 receptor activity was by for basal cellular hydrolysis as a function of the density of the receptors in transiently transfected HEK293 cells. a in which were transfected with of of a human B1 receptor and in for receptor expression by binding and and for activity by basal hydrolysis increased with of binding and the B1 A that the of the increase in hydrolysis as a function of the human B1 which may be as index of receptor activity and which we the index of basal activity, or T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar), was the human B1 receptor activity was that of the human B2 which of T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). show that the B1 receptor is constitutively and this activity is at receptor that be to in were with the B1 receptor that the constitutive activity was not a of the human receptor not and hydrolysis by the human B1 and B2 HEK293 transfected with of the B1 or B2 receptors were in the and and of and and for hydrolysis and binding a of the of and BK on the B1 and B2 are the in the in A and The are from to with in of the agonist at a to the human B1 to B1 a of hydrolysis of This which we the index of agonist-promoted receptor activity, or T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar), a increase the for the B1 receptor a similar increase was following of BK to the B2 T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). antagonists in their actions from to neutral to inverse activity and is thought to the of the receptor Several B1 receptor peptide antagonists peptides to the human B1 receptor expressed in HEK293 with of that was A and the at which was at B1 stimulation of hydrolysis in response to des-Arg9-BK in these the of the peptides the constitutive B1 receptor activity, and to these peptides are neutral antagonists at very weakly efficacious inverse on the human B1 receptor in HEK293 cells. A the of Asn121 in of the human B1 This is in and mutation of at this in in the constitutive of the receptors A. S. J. Res. 1997; PubMed Scopus Google Scholar, J. C. D. T. R. C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar, T. R. C. J. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, J. R. M. F. R.M. Mol. Pharmacol. 1996; Google Scholar, 1992; PubMed Scopus Google Scholar). to the that these in with in transmembrane that the receptor in One is that the of this is in the B1 receptor in a mutation of Asn121 not to increase in constitutive activity. that B1A121 a of hydrolysis that was that of the B1 the constitutive activity of the B1 Asn121 in in this the of to that by the agonist des-Arg10-KD, we of with the stimulation the of hydrolysis for this mutant only with for the receptor Furthermore, the of binding and the of to with the binding of the to this were and for the receptor and and of the was not by this mutation of B1 receptor peptide and antagonists on B1 receptors and of transiently transfected were to were by the in binding a of and and of and respectively. The are as the of at were by the in binding a of and and of and in the and of The are as the of at from the for from the in the of from the for of transiently transfected were to The were by the in binding a of and and of and respectively. The are as the of at The were by the in binding a of and and of and in the and of The are as the of at from the for from the in the of in a of agonist binding the of to of of activity and G of increase in the of to with the binding of binding to the B1 receptor and This that the agonist to to and the of the G protein-coupled state of the B1 receptor and that it is of G protein-coupled and on the of to with the binding of the to the receptor and with the of as a neutral it is to G protein-coupled and receptor of of increase in the of to with the binding of binding and The increase was not that it is or not this mutant is of the that mutation of Asn121 in the B1 receptor of the The in of and increase in affinity for B1A121 that the is the by that the B1 receptor was to mutation of this is in this may be for the activity of this The human B2 receptor a cluster of serines and threonines and in that is B2 receptors from and this cluster is important for agonist-promoted receptor activity by receptor and A. A. F. R.M. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar) and T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). mutation of this cluster increased B2 receptor activity leading to the thought that it is also important for constitutive receptor activity T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). The human B1 receptor serines and threonines in IC-IV and that are in the receptor the the and B1 in their only a to Furthermore, the human B1 receptor not to as a for A. K. C. M. 1999; PubMed Scopus Google Scholar). for the high constitutive activity of the B1 receptor be that this receptor critical serines and threonines in IC-IV that regulate such activity. this we first substituted IC-IV of the B2 which the in the B1 receptor to make in this the constitutive B1 receptor activity. The activity was also This also the constitutive activity and activity of B1A121 and alanine mutation of the in both to make and B1(B2ICIV)A121, to make the receptor both the A and and the cluster in B2 IC-IV that constitutive receptor activity. Furthermore, this appears to of the state of the receptor since it was both with and the Asn121 hydrolysis by the human receptor IC-IV A and HEK293 transfected with of the B1 B1(B2ICIV) or were in the and and of as and for hydrolysis and binding a of transfected with of B1A121 or were in the and and of as and for hydrolysis and binding a of and the of are the in the The are from to with in this we show that the human B1 BK receptor subtype exhibits high ligand-independent, constitutive activity. Despite the constitutive activity of the alanine mutation of Asn121 in in a further increase in receptor activity. the with IC-IV of the B2 which exhibits minimal activity, constitutive activity of the B1 receptor as as the activity of The of B2 IC-IV is partially due to the of serines and threonines that are important for B2 receptor but epitopes also to be show that constitutive activity depends on epitopes in both transmembrane and intracellular domains. We propose that the high constitutive B1 receptor activity is due primarily to the lack of epitopes in IC-IV that regulate such activity. Constitutive receptor activity a rationale for restricting the expression of the B1 receptor primarily to conditions of the for the B1 receptor is as high as the for the B2 is that this activity for agonist stimulation of the the to the of a receptor state with of a state by the Asn121 mutation that this agonist a in B1 receptor However, since the of B1 is Burch R.M. Scholar), constitutive receptor activity may a to the of a of agonist in receptors are but of are to the receptor constitutive receptor activity may with interleukin-1μ to rapidly the as for receptor (8Phagoo S.B. Poole S. Leeb-Lundberg L.M.F. Mol. Pharmacol. 1999; 56: 325-333Crossref PubMed Scopus (118) Google Scholar). The ligand-independent, constitutive activity that these receptors and and and that with a G to that the intracellular signal S. T. R.J. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar, Pharmacol. Rev. 1996; Google Scholar). these by binding to and the of these is that the is not to two receptor but with a of The that the of the state in these is important of the level of constitutive activity of a The transmembrane of and constitutively that this the of necessary to the receptor in state A. S. J. Res. 1997; PubMed Scopus Google Scholar). at a in by in the receptor and the B2 BK receptor to in such a since their mutation increase in activity J. C. D. T. R. C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar, T. R. C. J. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). This is in the B1 receptor mutation of this to a increase in the receptor activity on This mutation also the stimulation of receptor activity by the agonist to from to the of to and the of for with the binding of the to The lack of of the mutation on of the that this is The of this mutant to a state that is a B1 receptor agonist and that the receptor not on constitutive activity for The of the B1 receptor to the mutation of this that the activity of the receptor is not due to the of IC-IV domain that may be for constitutive receptor activity. that with in both G and and are in this domain, and both to activity. receptor activity be to the and of receptor epitopes which such we the B2 receptor to provide for a of IC-IV in of receptor activity T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). This receptor exhibits minimal activity. However, a in activity was following alanine mutation of a cluster of serines and threonines in IC-IV of this This cluster is a for agonist-promoted receptor A. A. F. R.M. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar) and important for B2 receptor T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar). the cluster a on the activity of this The of epitopes in IC-IV of this receptor was not since the level of B2 receptor activity is The human B1 receptor serines and threonines in but of are in B1 receptors from the B1 receptor is not A. K. C. M. 1999; PubMed Scopus Google Scholar), and it is to very S.A. Criscimagna N.L. Leeb-Lundberg L.M.F. Mol. Pharmacol. 1996; 50: 128-129PubMed Google Scholar) and A. S. J.M. D. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). The dramatic by B2 receptor IC-IV on the constitutive activity of the B1 receptor and the of this Furthermore, this with a of the and of activity of this mutation of the cluster in this partially the constitutive activity. This mutation that serines and threonines are important epitopes for constitutive activity. However, important is that these and the of in B2 receptor IC-IV that regulate receptor activity. Furthermore, this of the state of receptor since it was with the constitutive activity of both the B1 receptor and we that the high constitutive activity of the B1 receptor is at in a of the lack of epitopes in IC-IV that regulate such activity. of the and of the B1 receptor is that this receptor is or in healthy but is induced in response to which it mediates and to the (7Marceau F. Hess J.F. Bachvarov D.R. Pharmacol. Rev. 1998; 50: 357-386PubMed Google Scholar). The of the B1 receptor as as on the of this receptor J.B. Araujo R.C. Heppenstall P.A. Stucky C.L. Silva Jr., J.A. Walther T. Oliveira S.M. Pesquero J.L. Paiva A.C.M. Calixto J.B. Lewin G. Bader M. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 8140-8145Crossref PubMed Scopus (327) Google Scholar). are and the and of in tissue is B1 receptors are not in the of but a for the of the B1 receptor from the of two of this receptor D.R. M. S. F. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar, D.R. M. M. C. J. M. F. J. Am. 1998; PubMed Google Scholar). One of these a G in a of the and the increase in the activity of the B1 receptor the is in with and inflammatory The in the B1 receptor as a for with the of the function of this receptor in inflammation and D. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: PubMed Scopus Google Scholar). A of B1 antagonists are of are peptides and Several of these antagonists exhibit high and for the B1 The of constitutive B1 receptor activity the to inverse in the of these antagonists with this receptor this is as the of a to to and the state of the receptor not only activity but also activity of the This is in to neutral which are for receptor only activity. of the antagonists the constitutive B1 receptor activity and to a B1 receptor antagonists are either neutral or very weakly efficacious inverse agonists. is to the of and since these antagonists were from the high affinity and B2 receptor antagonists and by the C-terminal The B2 antagonists as efficacious inverse on the B2 receptor J. C. D. T. R. C. Mol. Pharmacol. 1999; PubMed Scopus Google Scholar, T. S.A. Leeb-Lundberg L.M.F. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus (50) Google Scholar, L.M.F. S.A. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar). the of these to for binding that the G state of the B2 The lack of inverse of was by the fact that the binding of this was not by the constitutive activity of the B1 receptor in this it is that inverse to be in the for the B1 Furthermore, inverse be to the of constitutive activity of B1 and in We D. J. for and D. Regoli for and F. for
32
Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
Jasmine Parma, Laurence Duprez, Jacqueline Van Sande et al. · Nature · 1993 · 923 citations
Medicine, Endocrinology, Genetics +12
Expression cloning of a human B1 bradykinin receptor.
John G. Menke, Joseph A. Borkowski, Kathleen K. Bierilo et al. · Journal of Biological Chemistry · 1994 · 465 citations · Full text